However, ADAM10 inhibition in cHL can be a double-edged sword because it might not only improve the therapy with anti-CD30 therapeutics but also favor the tumor-supporting, EV-based communication in cHL tissue. Here, TNFRSF8 is linked to classic Hodgkin lymphoma.